423 related articles for article (PubMed ID: 27102113)
1. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.
Raal FJ; Giugliano RP; Sabatine MS; Koren MJ; Blom D; Seidah NG; Honarpour N; Lira A; Xue A; Chiruvolu P; Jackson S; Di M; Peach M; Somaratne R; Wasserman SM; Scott R; Stein EA
J Lipid Res; 2016 Jun; 57(6):1086-96. PubMed ID: 27102113
[TBL] [Abstract][Full Text] [Related]
2. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
[TBL] [Abstract][Full Text] [Related]
3. The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.
Lambert G; Thedrez A; Croyal M; Ramin-Mangata S; Couret D; Diotel N; Nobécourt-Dupuy E; Krempf M; LeBail JC; Poirier B; Blankenstein J; Villard EF; Guillot E
Clin Sci (Lond); 2017 Feb; 131(4):261-268. PubMed ID: 28108631
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.
Shapiro MD; Minnier J; Tavori H; Kassahun H; Flower A; Somaratne R; Fazio S
J Am Heart Assoc; 2019 Feb; 8(4):e010932. PubMed ID: 30755061
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
O'Donoghue ML; Fazio S; Giugliano RP; Stroes ESG; Kanevsky E; Gouni-Berthold I; Im K; Lira Pineda A; Wasserman SM; Češka R; Ezhov MV; Jukema JW; Jensen HK; Tokgözoğlu SL; Mach F; Huber K; Sever PS; Keech AC; Pedersen TR; Sabatine MS
Circulation; 2019 Mar; 139(12):1483-1492. PubMed ID: 30586750
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.
Romagnuolo R; Scipione CA; Boffa MB; Marcovina SM; Seidah NG; Koschinsky ML
J Biol Chem; 2015 May; 290(18):11649-62. PubMed ID: 25778403
[TBL] [Abstract][Full Text] [Related]
7. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.
Julius U; Tselmin S; Schatz U; Fischer S; Bornstein SR
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):45-50. PubMed ID: 30838555
[TBL] [Abstract][Full Text] [Related]
9. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
Watts GF; Chan DC; Somaratne R; Wasserman SM; Scott R; Marcovina SM; Barrett PHR
Eur Heart J; 2018 Jul; 39(27):2577-2585. PubMed ID: 29566128
[TBL] [Abstract][Full Text] [Related]
10. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
[TBL] [Abstract][Full Text] [Related]
11. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
12. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
[TBL] [Abstract][Full Text] [Related]
13. A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels.
Cao YX; Liu HH; Li S; Li JJ
Am J Cardiovasc Drugs; 2019 Feb; 19(1):87-97. PubMed ID: 30229525
[TBL] [Abstract][Full Text] [Related]
14. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
[TBL] [Abstract][Full Text] [Related]
15. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
[TBL] [Abstract][Full Text] [Related]
16. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
Stiekema LCA; Stroes ESG; Verweij SL; Kassahun H; Chen L; Wasserman SM; Sabatine MS; Mani V; Fayad ZA
Eur Heart J; 2019 Sep; 40(33):2775-2781. PubMed ID: 30561610
[TBL] [Abstract][Full Text] [Related]
17. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.
Bittner VA; Giugliano RP; Brinton EA; Guyton JR
J Clin Lipidol; 2018; 12(4):835-843. PubMed ID: 30055750
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a).
Zhang X; Stiekema LCA; Stroes ESG; Groen AK
Lipids Health Dis; 2020 May; 19(1):91. PubMed ID: 32393252
[TBL] [Abstract][Full Text] [Related]
20. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.
Raal FJ; Giugliano RP; Sabatine MS; Koren MJ; Langslet G; Bays H; Blom D; Eriksson M; Dent R; Wasserman SM; Huang F; Xue A; Albizem M; Scott R; Stein EA
J Am Coll Cardiol; 2014 Apr; 63(13):1278-1288. PubMed ID: 24509273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
